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Abstract
Objective—Despite variability in the burden of elevated depressive symptoms by sex and race 
and differences in the incidence of metabolic syndrome, few prior studies describe the longitudinal 
association of depressive symptoms with metabolic syndrome in a diverse cohort. We tested 
whether baseline and time-varying depressive symptoms were associated with metabolic syndrome 
incidence in black and white men and women from the Coronary Artery Risk Development in 
Young Adults (CARDIA) study.
Methods—Participants reported depressive symptoms using the Center for Epidemiologic 
Studies Depression (CES-D) Scale at 4 examinations between 1995 and 2010. At those same 
examinations, metabolic syndrome was determined. Cox proportional hazards models were used 
to examine associations of depressive symptoms on development of metabolic syndrome in 3,208 
participants without metabolic syndrome at baseline.
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Results—Over 15 years, the incidence rate of metabolic syndrome (per 10,000 person-years) 
varied by race and sex with the highest rate in black women (279.2), followed by white men 
(241.9), black men (204.4) and white women (125.3). Depressive symptoms (per SD higher) were 
associated with incident metabolic syndrome in white men (hazard ratio [HR]=1.25, 95% 
confidence interval [CI]: 1.08, 1.45) and white women (HR=1.17, 95% CI: 1.00, 1.37) following 
adjustment for demographic characteristics and health behaviors. There was no significant 
association between depression and metabolic syndrome among black men or black women.
Conclusion—Higher depressive symptoms contribute modestly to the onset of metabolic 
syndrome among white adults.
Keywords
Depressive Symptoms; Metabolic Syndrome; race; longitudinal
INTRODUCTION
Metabolic syndrome is an established risk factor for coronary heart disease and diabetes (1). 
Prior studies have described an association of depression or elevated depressive symptoms 
with high blood pressure, (2–5) large waist circumference, (5–9) elevated fasting blood 
glucose (6),(8), and increased diabetes risk (10, 11)—each of which are components of the 
metabolic syndrome. However, findings on the relationship between depression and 
metabolic syndrome are less consistent. Cross-sectional studies report both positive (4, 6, 8, 
9, 12) and no association (2–4) (13, 14) with metabolic syndrome. By contrast, longitudinal 
studies do report a significant positive association (7, 13, 14). However, some of these 
studies were restricted to females and the majority were conducted predominately in one 
race/ethnic group (90% white) (13, 14).
Demographic differences are observed in the prevalence of metabolic syndrome, with rates 
higher among blacks (15, 16). Although the risk factors for metabolic syndrome are well 
characterized (17, 18) (19), the contribution of depressive symptoms is understudied. 
Population screening studies estimate that the prevalence of major depressive disorder and 
elevated depressive symptoms is higher in women as compared with men (20, 21). Several 
studies suggest that blacks having higher depressive symptoms compared with whites (22) 
(23) (24, 25). Despite demographic differences in rates of metabolic syndrome by race and 
depression, few prior studies have had adequate sample size and longitudinal follow up to 
test the hypothesis that elevated depressive symptoms are associated with incident metabolic 
syndrome within population subgroups.
METHODS
Participants
We tested our hypotheses in the Coronary Artery Risk Development in Young Adults 
(CARDIA) study, a multicenter, longitudinal investigation of cardiovascular disease risk 
starting in young adulthood. The study began in 1985–1986 with 5115 black and white 
adults between the ages of 18 and 30. Participants were recruited from four metropolitan 
areas (Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA). Participants 
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were reexamined 2, 5, 7, 10, 15, 20, and 25 years after study initiation. The sample for our 
analysis began at the 10 year follow up examination in 1995–1996 which is the first visit 
when both depressive symptoms and metabolic syndrome components were available. 
Participants were then followed through 2010 for changes in depressive symptoms and 
outcomes. The 10 year follow up examination will now be referenced as baseline 
throughout. The institutional review boards for the protection of human subjects for the 
participating study sites provided approval for the study, and written informed consent was 
obtained for all participants.
There were 3,950 participants completed the examination in 1995–96. We excluded 
participants from our analysis sample for the following reasons: pregnancy (n=28), unable to 
determine metabolic syndrome status (n=68), prevalent metabolic syndrome (n=429), unable 
to determine metabolic syndrome incidence over follow-up (n=216) or missing depressive 
symptoms at our baseline examination (n= 1). Our final analysis sample included 3,208 
participants. When we compared the characteristics of participants who were free from 
metabolic syndrome at baseline (1995–96) but who were excluded for the other reasons 
above (n=217), we observed that excluded participants were slightly younger (34.2 vs. 34.9 
years, p=0.003), more likely to be black (64.1 vs. 46.8%, p<0.001) and more likely to be 
current smokers (42.6% vs. 23.9%, p<0.001).
Measures
Depressive Symptoms—Depressive symptoms were measured with the Center for 
Epidemiologic Studies Depression Scale (CES-D) (26). The 20-item CES-D measure was 
used to generate a single score to assess the participant’s mood during the previous week. 
The possible range of scores is 0 to 60, and scores >=16 have been correlated with major 
depressive disorder (26). To capture the potential for depressive symptoms to vary over time, 
we studied the influence of multiple measures of CES-D for four exam years (1995–1996, 
2000–2001, 2005–2006 and 2009–2010) using longitudinal modeling. Our primary measure 
of depressive symptoms was the continuously measured CES-D score and our secondary 
measure categorized the CES-D score to compare those with elevated depressive symptoms 
(CES-D >=16) to those without elevated depressive symptoms.
Metabolic Syndrome—Participants fasted for at least 12 hours and blood was drawn 
according to standardized protocols across field centers (27). Glucose (28) and lipids (high 
density lipoprotein [HDL] cholesterol and triglycerides) (29),(30) were determined at a 
central laboratory (27). After a 5-minute rest, blood pressure was measured from 
participants in the seated position three times; the average of the last two measurements was 
used. Waist circumference was determined as the average of two waist circumference 
measures at captured at the minimum abdominal girth (nearest 0.5 cm) from participants 
standing upright.
Metabolic syndrome was defined using modified National Cholesterol Education Program – 
Adult Treatment Panel III (NCEP-ATP III) criteria (31). Participants were identified as 
having metabolic syndrome if they had at least three of the following cardiovascular risk 
factors: 1) fasting glucose ≥ 100 mg/dL or diabetes medication, 2) waist circumference >88 
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cm (women) or > 102 cm (men), 3) systolic blood pressure ≥ 130 mmHg or diastolic blood 
pressure ≥ 85 mmHg or hypertension medicine 4) triglycerides ≥ 150 mg/dL, or 5) HDL 
cholesterol < 50 mg/dL in women or < 40 mg/dL in men (32). We excluded participants who 
had metabolic syndrome at the baseline examination for our study in order to determine 
incident metabolic syndrome. Incident metabolic syndrome was determined at the time that 
participants first met the above criteria at any of the following examinations: 2000–2001, 
2005–2006 and 2009–2010.
Covariates—We selected covariates that demonstrated an association with both depressive 
symptoms and metabolic syndrome in prior studies. Education (years), smoking status 
(“never”, vs “former”, vs “current”), and alcohol intake (“none” vs. “<=2 drinks/day or last 
month’s maximum <=4 drinks in 1 day for males or <=1 drink/day or last month’s 
maximum <=3 drinks in 1 day for females” vs. “ >2 drinks/day or last month’s maximum >4 
drinks in 1day for males or >1 drink/day or last month’s maximum >3 drinks in 1 day for 
females”) were determined using self-reported questionnaires. Physical activity was assessed 
by an interviewer-administered questionnaire, which assessed the amount of time spent in 13 
different activities of either heavy (> 5 metabolic equivalents (METS)) or moderate (3 to 4 
METS) intensity during the last year (33). A medical history questionnaire was used to 
quantify self-reported antidepressant medication use. Covariates were measured at each of 
the follow up examinations (2000–2001, 2005–2006 and 2009–2010).
Data Analysis
We made an a priori decision to stratify our findings by race and sex given the relationship 
between depression and metabolic syndrome components has varied by race and sex (7, 34, 
35). However, we did test for the presence of interactions between the main effect 
(depressive symptoms) and race from a sex-pooled model as well as sex from a race-pooled 
model.
The distribution of covariates in 1995–1996 (baseline) is presented using means for 
continuous variables and proportions for categorical variables. T-tests and chi-square tests 
were used to compare the covariates by race within sex categories. Follow-up time was 
determined between baseline (1995–1996) and the visit at which incident metabolic 
syndrome was identified. Among participants who did not experience metabolic syndrome, 
follow-up time was calculated through the last clinic examination date they attended. 
Person-years were calculated as a product of the number of participants by their follow-up 
time and used in the denominator of our calculation of event rates per 10,000 person-years. 
After testing and confirming that the proportional hazards assumption was met using log-log 
survival plots, we modeled the association between depressive symptoms and metabolic 
syndrome in unadjusted and multivariable adjusted models. Because metabolic syndrome 
was identified at only three follow-up examinations, there is the potential for events to have 
the same survival time (heavily “tied” data). We handled ties using the Efron method which 
outperforms other methods in simulation models (36). Our first multivariable model 
included demographic characteristics from 1995–1996 including age and education and our 
second multivariable model additionally adjusted for physical activity, alcohol intake, 
smoking status, and antidepressant use which are also measured at baseline. Diabetes 
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development was not included as a time dependent covariate. Our findings are presented as 
hazard ratios and 95% confidence intervals. To account for the potential for depressive 
symptoms to vary over time, we repeated our analyses using time varying CES-D. In those 
Cox proportional hazards models, we used time-varying covariates to adjust for physical 
activity, alcohol intake, smoking status, and antidepressant use measured at each follow up 
examination (2000–2001, 2005–2006 and 2009–2010). All analyses were repeated using 
categorically elevated depressive symptoms. Statistical significance was determined by a p 
value <0.05 (two-tailed). Version 9.3 of the SAS software package (SAS Institute, Cary, NC, 
USA) was used for all analyses.
RESULTS
Sample characteristics
Participants were aged 28 to 40 years at the time of the 10 year follow-up examination in 
1995–96. The distribution of cardiovascular disease risk factors stratified by race and sex is 
presented in Table 1. Among men, black participants were younger, nearly twice as likely to 
be current smokers (36% in black men and 20% in white men) and had higher systolic and 
diastolic blood pressure. Black men had a higher mean depressive symptom score and were 
more likely to report elevated depressive symptoms (CES-D≥16) than white participants. 
Black women were younger but had less favorable measures of physical activity, cigarette 
smoking, fasting glucose, waist circumference, and blood pressure than white women. Mean 
depressive symptom scores and the proportion with elevated depressive symptoms was 
higher among black as compared with white women.
Over 10 years of follow-up, the rate of metabolic syndrome was markedly higher in black 
women (279.2 per 10,000 person-years) compared with white women (125.3 per 10,000 
person-years) whereas rates of metabolic syndrome were lower in black men (204.4 per 
10,000 person-years) versus white men (241.9 per 10,000 person-years).
Prior to modeling the relationship of baseline depressive symptoms with incident metabolic 
syndrome, we confirmed that there was a significant interaction between depressive 
symptoms and race (χ2 = 9.03, p < .003). Although sex did not modify the association (χ2 = 
2.15 p = 0.14) further, we present stratified results given the a priori objective to present 
stratified findings. Elevated depressive symptoms, measured per standard deviation higher 
score, are associated with significant elevations in the metabolic syndrome incidence in 
white men and women (Table 2). For the white men, these results appear to be driven by the 
positive association between elevated depressive symptoms and high triglycerides or low 
HDL (Table S1, Supplemental Digital Content 1). For the white women, these results appear 
to be driven by the positive association between elevated depressive symptoms and high 
fasting glucose or taking diabetes medication (Table S1).These findings persisted, though 
attenuated, following additional statistical adjustment for antidepressant medication use, 
total physical activity, alcohol intake and smoking status. In parallel, categorically elevated 
depressive symptoms as defined by CES-D≥16 were associated with significantly higher 
metabolic syndrome incidence in white men and women, though the findings were only 
statistically significant in crude models among the men and in demographic adjusted models 
for women. Among black participants, there was no association of either continuously 
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determined depressive symptoms or categorically elevated depressive symptoms with 
incident metabolic syndrome.
In a secondary analysis where we allowed depressive symptoms to vary over time using 
time-varying covariates, we again found a significant positive association between 
depressive symptoms and incident metabolic syndrome among white men and women (data 
not shown). There was again no association of time-varying depressive symptoms with 
incident metabolic syndrome in black women or men.
DISCUSSION
We report for the first time, a positive association of elevated depressive symptoms with 
metabolic syndrome in white, but not black, middle-aged adults. Our observation persisted 
following statistical adjustment for relevant health behaviors and was consistent whether we 
used a single measure of depressive symptoms at baseline or allowed depressive symptoms 
to vary over time. There was no evidence of heterogeneity in this association by sex. To our 
knowledge, ours is the first longitudinal study to highlight that the relationship of depressive 
symptoms with metabolic syndrome incidence may be driven by the strength of association 
among white adults.
Our findings are consistent with existing longitudinal studies carried out in American and 
Israeli adults (7, 13, 14). Because prior longitudinal studies did not compare the burden of 
depressive symptoms or major depressive disorder by race/ethnicity, it is not known whether 
depressive symptom reporting in whites was also was relatively lower in those populations 
as it was in ours. Even though the burden of depressive symptoms was not particularly high 
among white participants, one pathway by which elevated symptoms may be associated with 
metabolic syndrome is through adverse health behaviors. Participants who are experiencing 
depression may be less likely to adhere to healthy lifestyle recommendations (37–39), thus 
placing themselves at risk for developing metabolic syndrome components and the 
metabolic syndrome. Among women, we observed that our associations were attenuated to 
borderline significance when we adjusted for health behaviors such as physical activity, 
alcohol intake, smoking status and antidepressant use. These observations suggest one 
pathway by which depressive symptoms could be associated with incident metabolic 
syndrome.
It is equally plausible that depression and/or the behaviors adopted to cope with depression 
act by inducing physiologic changes that increase risk for metabolic syndrome. For example, 
dysregulation of the autonomic nervous system and hyperactivity of the hypothalamic 
pituitary adrenal (HPA) axis (40, 41) may lead to the development of insulin resistance (42)
—an underlying features of the metabolic syndrome. Elevated cortisol, a consequence of an 
activated HPA axis and indicator of chronic stress, may play a role in the association. 
Vogelzangs et al. (9) found that when both depression and high cortisol levels are present, 
the odds of metabolic syndrome increases. Muhtz (5) revealed that elevated cortisol partially 
mediated depressive symptoms’ association with several components of metabolic 
syndrome.
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Our finding that there was no association between depressive symptoms and the 
development of metabolic syndrome among black men and women was unexpected. Two 
studies have found elevated depressive symptoms and major depressive disorder are 
associated with incident diabetes in multi-racial samples, but they did not test whether the 
associations were differential by race/ethnicity (43) (44). It is possible that the metabolic 
syndrome is a unique disease phenotype in black vs. white adults. In particular, the 
syndrome is most commonly comprised of elevations in hypertension, diabetes and obesity 
in blacks and less commonly includes dyslipidemia. Given prior studies demonstrating that 
elevated depressive symptoms are associated with incident hypertension (34) and diabetes 
(45–47) in blacks and prevalent obesity in blacks (35), we would have expected these 
relationships to underlie a significant finding in our study. Hypertension, diabetes and 
obesity are so highly prevalent among US blacks that the origins of disease may lie in 
behavioral or other social factors that, when compared with depressive symptoms, are much 
more strongly associated with metabolic disorders. Alternatively, our measure of depressive 
symptoms, the CES-D, may not capture the aspects of depressive symptomatology that are 
directly associated with the somatic changes that could predispose to metabolic syndrome. 
These hypotheses to explain the null association warrant testing in future studies and our 
findings should be verified in other datasets using different measures of depressive 
symptoms.
One limitation of our study is that we were unable to account for the potential influence of 
diet since diet assessment in CARDIA did not coincide with the baseline assessment in our 
analysis (1995–1996). Excess energy intake with weight gain may account for the 
association of depression and the development metabolic syndrome in our study. However, 
because adults who are experiencing elevated depressive symptoms may be just as likely to 
over-eat as to under-eat, it is not clear how this adjustment would have affected our findings. 
Another limitation of this study is that there is a 5-year window between study visits. 
However, for it to bias the association we would have to hypothesize that one group (those 
with or without elevated depressive symptoms) would have been more likely to develop 
metabolic syndrome at a visit vs. in between a visit. There is no reason for us to assume this 
differential development of metabolic syndrome by our exposure variable, thus the influence 
on our effect estimates would not lead to a bias away from the null. We used survival 
analysis and defined time using discrete intervals to account for heavily “tied” data (events 
could happen at only 3 timepoints during the study). When we compared our findings using 
logistic regression analysis (had metabolic syndrome vs. did not), our results were similar. 
Statistical adjustment for potential confounders may not have account for all of the observed 
effect and residual confounding may remain.
A strength of our study is the relatively large sample size with equal numbers of black and 
white adults. Additionally, we were able to confirm that the association was the same 
whether a single measure of depressive symptoms were used or if depressive symptoms 
were permitted to vary over time as they do clinically (48).
In conclusion, depressive symptoms may contribute to the development of metabolic 
syndrome in white adults. Our findings add to the growing body of research highlighting the 
adverse health effects of elevated depressive symptoms in some population subgroups. 
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Future studies should investigate the contribution of stress-related biological mechanisms 
(i.e. elevated cortisol) that may underlie the association of depressive symptoms and 
metabolic syndrome.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
Event Rates and Cox Proportional Hazards Analysis of Baseline Depressive Symptoms with Incident 
Metabolic Syndrome (1995–1996)
Men Women
Black (n=634) White (n=796) Black (n= 868) White (n=910)
Events, N 160 242 302 153
Events, % 25.2 30.4 34.8 16.8
Rate per 10,000 PY 204.4 241.9 279.2 125.3
Continuous Depressive Symptoms
(HR; CI 95%)
M1: Unadjusted 0.95 (0.81, 1.11) 1.31 (1.14, 1.51) 1.04 (0.95, 1.14) 1.24 (1.07, 1.44)
M2a 0.98 (0.83, 1.15) 1.26 (1.10, 1.45) 0.99 (0.90, 1.09) 1.20 (1.03, 1.39)
M3: 1.02 (0.86, 1.21) 1.25 (1.08, 1.45) 0.99 (0.90, 1.10) 1.17 (1.00, 1.37)
Categorical Depressive Symptoms
(HR; CI 95%; CES-D < 16 is reference)
M1: Unadjusted 0.92 (0.63, 1.35) 1.50 (1.07, 2.10) 1.16 (0.91, 1.47) 1.66 (1.15, 2.40)
M2: 1.06 (0.72, 1.56) 1.34 (0.96, 1.89) 1.00 (0.78, 1.28) 1.49 (1.03, 2.16)
M3 1.09 (0.73, 1.64) 1.27 (0.90, 1.80) 1.00 (0.77, 1.29) 1.40 (0.95, 2.05)
Metabolic Syndrome was measured between Year 15 and Year 25 and is composed of at least three of the following cardiovascular risk factors: 1) 
Fasting glucose ≥ 100 mg/dL or diabetes medication, 2) Waist circumference > 88 cm (women) or > 102 cm (men), 3) Systolic blood pressure ≥ 
130 mmHg or diastolic blood pressure ≥ 85 mmHg or hypertension medicine 4) Triglycerides ≥ 150 mg/dL, 5) HDL cholesterol < 50 mg/dL in 
women or < 40 mg/dL in men.
M2: Adjusted for age and education M3: M2 + total physical activity, alcohol use, smoking status, and antidepressant use.
Continuous depressive symptoms should be interpreted as 1 SD unit. Baseline is Year 10.
Bold font indicates that the hazard ratio is statistically significant at the .05 level.
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